Shots:

• The termination is based on two ongoing evaluation studies- P-II study (NCT02310763) and open label study(NCT02907619)- which didn’t meet efficacy endpoints for showing the difference in mean change from baseline in 4 Stair Climb (in sec) with one year of treatment vs PBO
• The P-II (N=121 boys) aged (6 to 15yrs.) administering monthly IV doses designed for two years and open-label to evaluate long-term safety and efficacy of domagrozumab
• The studies were not terminated for safety reasons and company will review the data. Pfizer is also conducting a trial in DMD with gene therapy

/ article | Ref: Pfizer | Image:  Pfizer